questionText: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of access to Tofersen through the Early Access Programme for people with SOD1 motor neurone disease.
answerText: Companies may put in place Early Access Programmes (EAPs) to allow for early access to new medicines that do not yet have a marketing authorisation. Participation in EAPs is decided at an individual National Health Service trust level, and under these pro...
heading: Tofersen